EBP50 regulates the apoptosis of pancreatic cancer cells by decreasing the expression levels of Bcl‑2

Ji,Mengyao; Yuan,Lei; Lv,Xiaoguang; Dong,Weiguo; Peng,Xiulan

doi:10.3892/etm.2014.1831

EBP50 regulates the apoptosis of pancreatic cancer cells by decreasing the expression levels of Bcl‑2

Authors:
- Mengyao Ji
- Lei Yuan
- Xiaoguang Lv
- Weiguo Dong
- Xiulan Peng
View Affiliations

Affiliations: Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China, Criminal Science and Technology Studio, Chongqing Banan Police Security Bureau, Chongqing, Chongqing 401320, P.R. China, Department of Oncology, The Fifth Hospital of Wuhan, Wuhan 430050, P.R. China
Published online on: July 7, 2014 https://doi.org/10.3892/etm.2014.1831
Pages: 919-924

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Increasing evidence has demonstrated that ezrin‑radixin‑moesin (ERM)‑binding phosphoprotein 50 (EBP50) is involved in the malignant transformation of numerous human cancers. The present study investigated the involvement of EBP50 overexpression in the tumorigenicity of pancreatic cancer (PC). The results revealed that overexpression of EBP50 suppressed cell growth, promoted cell apoptosis and arrested G1‑to‑S phase progression in two human PC cell lines. Overexpression of EBP50 also suppressed B-cell lymphoma 2 (Bcl‑2) expression. Furthermore, nude mouse tumor xenograft models were established by the subcutaneous injection of cell lines stably transfected with an EBP50‑expressing plasmid. The in vivo data indicated that overexpression of EBP50 inhibited the growth of the PC tumors and induced cell apoptosis. Thus, the present study demonstrated that EBP50 overexpression induces growth inhibition and apoptosis in PC by decreasing Bcl‑2 expression. The results suggest that EBP50 may function as a potential tumor suppressor in vivo and in vitro.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Mackenzie GG, Huang L, Alston N, et al: Targeting mitochondrial STAT3 with the novel phospho-valproic acid (MDC-1112) inhibits pancreatic cancer growth in mice. PLoS One. 8:e615322013. View Article : Google Scholar : PubMed/NCBI
3	Georgescu MM, Morales FC, Molina JR and Hayashi Y: Roles of NHERF1/EBP50 in cancer. Curr Mol Med. 8:459–468. 2008. View Article : Google Scholar : PubMed/NCBI
4	Ghaneh P, Costello E and Neoptolemos JP: Biology and management of pancreatic cancer. Postgrad Med J. 84:478–497. 2008. View Article : Google Scholar
5	Clapéron A, Guedj N, Mergey M, et al: Loss of EBP50 stimulates EGFR activity to induce EMT phenotypic features in biliary cancer cells. Oncogene. 31:1376–1388. 2012.PubMed/NCBI
6	Sun C, Zheng J, Cheng S, Feng D and He J: EBP50 phosphorylation by Cdc2/Cyclin B kinase affects actin cytoskeleton reorganization and regulates functions of human breast cancer cell line MDA-MB-231. Mol Cells. 36:47–54. 2013. View Article : Google Scholar : PubMed/NCBI
7	Kreimann EL, Morales FC, de Orbeta-Cruz J, et al: Cortical stabilization of beta-catenin contributes to NHERF1/EBP50 tumor suppressor function. Oncogene. 26:5290–5299. 2007. View Article : Google Scholar : PubMed/NCBI
8	Shibata T, Chuma M, Kokubu A, Sakamoto M and Hirohashi S: EBP50, a beta-catenin-associating protein, enhances Wnt signaling and is over-expressed in hepatocellular carcinoma. Hepatology. 38:178–186. 2003. View Article : Google Scholar : PubMed/NCBI
9	Lee YJ, Choi IK, Sheen YY, Park SN and Kwon HJ: Identification of EBP50 as a specific biomarker for carcinogens via the analysis of mouse lymphoma cellular proteome. Mol Cells. 33:309–316. 2012. View Article : Google Scholar : PubMed/NCBI
10	Lv XG, Ji MY, Dong WG, et al: EBP50 gene transfection promotes 5-fluorouracil-induced apoptosis in gastric cancer cells through Bax- and Bcl-2-triggered mitochondrial pathways. Mol Med Rep. 5:1220–1226. 2012.
11	Molina JR, Morales FC, Hayashi Y, Aldape KD and Georgescu MM: Loss of PTEN binding adapter protein NHERF1 from plasma membrane in glioblastoma contributes to PTEN inactivation. Cancer Res. 70:6697–6703. 2010. View Article : Google Scholar : PubMed/NCBI
12	Fraenzer JT, Pan H, Minimo L Jr, Smith GM, Knauer D and Hung G: Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation. Int J Oncol. 23:1493–1500. 2003.PubMed/NCBI
13	Morales FC, Takahashi Y, Kreimann EL and Georgescu MM: Ezrin-radixin-moesin (ERM)-binding phosphoprotein 50 organizes ERM proteins at the apical membrane of polarized epithelia. Proc Natl Acad Sci USA. 101:17705–17710. 2004. View Article : Google Scholar : PubMed/NCBI
14	Lin YY, Hsu YH, Huang HY, et al: Aberrant nuclear localization of EBP50 promotes colorectal carcinogenesis in xenotransplanted mice by modulating TCF-1 and β-catenin interactions. J Clin Invest. 122:1881–1894. 2012.PubMed/NCBI
15	Morales FC, Hayashi Y, van Pelt CS and Georgescu MM: NHERF1/EBP50 controls lactation by establishing basal membrane polarity complexes with prolactin receptor. Cell Death Dis. 3:e3912012. View Article : Google Scholar : PubMed/NCBI
16	Ji MY, Fan DK, Lv XG, Peng XL, Lei XF and Dong WG: The detection of EBP50 expression using quantum dot immunohistochemistry in pancreatic cancer tissue and down-regulated EBP50 effect on PC-2 cells. J Mol Histol. 43:517–526. 2012. View Article : Google Scholar : PubMed/NCBI
17	Pan Y, Wang L and Dai JL: Suppression of breast cancer cell growth by Na⁺/H⁺ exchanger regulatory factor 1 (NHERF1). Breast Cancer Res. 8:R632006. View Article : Google Scholar : PubMed/NCBI
18	Guo J, Gao J, Li Z, et al: Adenovirus vector-mediated Gli1 siRNA induces growth inhibition and apoptosis in human pancreatic cancer with Smo-dependent or Smo-independent Hh pathway activation in vitro and in vivo. Cancer Lett. 339:185–194. 2013. View Article : Google Scholar : PubMed/NCBI
19	Gu WJ and Liu HL: Induction of pancreatic cancer cell apoptosis, invasion, migration, and enhancement of chemotherapy sensitivity of gemcitabine, 5-FU, and oxaliplatin by hnRNP A2/B1 siRNA. Anticancer Drugs. 24:566–576. 2013.PubMed/NCBI
20	Li X, Yan J, Wang L, et al: Beclin1 inhibition promotes autophagy and decreases gemcitabine-induced apoptosis in Miapaca2 pancreatic cancer cells. Cancer Cell Int. 13:262013. View Article : Google Scholar : PubMed/NCBI
21	Boyer C, Teo J, Phillips P, et al: Effective delivery of siRNA into cancer cells and tumors using well-defined biodegradable cationic star polymers. Mol Pharm. 10:2435–2444. 2013. View Article : Google Scholar : PubMed/NCBI
22	Morales FC, Takahashi Y, Momin S, Adams H, Chen X and Georgescu MM: NHERF1/EBP50 head-to-tail intramolecular interaction masks association with PDZ domain ligands. Mol Cell Biol. 27:2527–2537. 2007. View Article : Google Scholar : PubMed/NCBI
23	Hayashi Y, Molina JR, Hamilton SR and Georgescu MM: NHERF1/EBP50 is a new marker in colorectal cancer. Neoplasia. 12:1013–1022. 2010.PubMed/NCBI
24	Li X, Xu WM, Yin TL, Zhao QH, Peng LY and Yang J: Temporal and spatial regulation of ezrin-radixin-moesin-binding phosphoprotein-50-kDa (EBP50) during embryo implantation in mouse uterus. Int J Mol Sci. 13:16418–16429. 2012. View Article : Google Scholar : PubMed/NCBI
25	Yao W, Feng D, Bian W, et al: EBP50 inhibits EGF-induced breast cancer cell proliferation by blocking EGFR phosphorylation. Amino Acids. 43:2027–2035. 2012. View Article : Google Scholar : PubMed/NCBI